Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme

被引:43
作者
Gabbiani, Chiara [2 ]
Massai, Lara [1 ]
Scaletti, Federica [1 ]
Michelucci, Elena [3 ]
Maiore, Laura [4 ]
Cinellu, Maria Agostina [4 ]
Messori, Luigi [1 ]
机构
[1] Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy
[2] Univ Pisa, Dept Chem & Ind Chem, I-56126 Pisa, Italy
[3] Univ Florence, Mass Spectrometry Ctr CISM, I-50019 Sesto Fiorentino, Italy
[4] Univ Sassari, Dept Chem & Pharm, I-07100 Sassari, Italy
来源
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY | 2012年 / 17卷 / 08期
关键词
Anticancer drugs; Proteins; Gold compounds; Mechanism of action; Mass spectrometry; SERUM-ALBUMIN; THIOREDOXIN REDUCTASE; SOLUTION CHEMISTRY; ANTIPROLIFERATIVE PROPERTIES; GOLD(III) COMPLEXES; BINDING PROPERTIES; BIPYRIDYL LIGANDS; MASS-SPECTROMETRY; ANTICANCER DRUGS; CANCER-CELLS;
D O I
10.1007/s00775-012-0952-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein metalation processes are crucial for the mechanism of action of several anticancer metallodrugs and warrant deeper characterisation. We have explored the reactions of three cytotoxic gold(III) compounds-namely [(bipy(2Me))(2)Au-2(mu-O)(2)][PF6](2) (where bipy(2Me) is 6,6'-dimethyl-2,2'-bipyridine) (Auoxo6), [(phen(2Me))(2)Au-2(mu-O)(2)][PF6](2) (where phen(2Me) is 2,9-dimethyl-1,10-phenanthroline) (Au(2)phen) and [(bipy(dmb)-H)Au(OH)][PF6] [where bipy(dmb)-H is deprotonated 6-(1,1-dimethylbenzyl)-2,2'-bipyridine] (Aubipyc)-with two representative model proteins, i.e. horse heart cytochrome c and hen egg white lysozyme, through UV-visible absorption spectroscopy and electrospray ionisation mass spectrometry (ESI MS) to characterise the inherent protein metalation processes. Notably, Auoxo6 and Au(2)phen produced stable protein adducts where one or more "naked" gold(I) ions are protein-coordinated; very characteristic is the case of cytochrome c, which upon reaction with Auoxo6 or Au(2)phen preferentially forms "tetragold" adducts with four protein-bound gold(I) ions. In turn, Aubipyc afforded monometalated protein adducts where the structural core of the gold(III) centre and its +3 oxidation state are conserved. Auranofin yielded protein derivatives containing the intact auranofin molecule. Additional studies were performed to assess the role played by a reducing environment in protein metalation. Overall, the approach adopted provides detailed insight into the formation of metallodrug-protein derivatives and permits trends, peculiarities and mechanistic details of the underlying processes to be highlighted. In this respect, electrospray ionisation mass spectrometry is a very straightforward and informative research tool. The protein metalation processes investigated critically depend on the nature of both the metal compound and the interacting protein and also on the solution conditions used; thus, predicting with accuracy the nature and the amounts of the adducts formed for a given metallodrug-protein pair is currently extremely difficult.
引用
收藏
页码:1293 / 1302
页数:10
相关论文
共 39 条
[21]   Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria [J].
McKeage, MJ ;
Maharaj, L ;
Berners-Price, SJ .
COORDINATION CHEMISTRY REVIEWS, 2002, 232 (1-2) :127-135
[22]   X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins [J].
Messori, L. ;
Balerna, A. ;
Ascone, I. ;
Castellano, C. ;
Gabbiani, C. ;
Casini, A. ;
Marchioni, C. ;
Jaouen, G. ;
Castellano, A. Congiu .
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2011, 16 (03) :491-499
[23]   A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts [J].
Milacic, Vesna ;
Chen, Di ;
Ronconi, Luca ;
Landis-Piwowar, Kristin R. ;
Fregona, Dolores ;
Dou, Q. Ping .
CANCER RESEARCH, 2006, 66 (21) :10478-10486
[24]   INTERACTIONS OF GOLD COORDINATION-COMPLEXES WITH DNA [J].
MIRABELLI, CK ;
SUNG, CM ;
ZIMMERMAN, JP ;
HILL, DT ;
MONG, S ;
CROOKE, ST .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (09) :1427-1433
[25]   Thioredoxin reductase as a novel molecular target for cancer therapy [J].
Nguyen, Phuongmai ;
Awwad, Rania T. ;
Smart, Dee Dee K. ;
Spitz, Douglas R. ;
Gius, David .
CANCER LETTERS, 2006, 236 (02) :164-174
[26]  
Nobili S, 2010, MED RES REV, V30, P550, DOI 10.1002/med.20168
[27]   DISPLAY AND ANALYSIS OF PATTERNS OF DIFFERENTIAL ACTIVITY OF DRUGS AGAINST HUMAN-TUMOR CELL-LINES - DEVELOPMENT OF MEAN GRAPH AND COMPARE ALGORITHM [J].
PAULL, KD ;
SHOEMAKER, RH ;
HODES, L ;
MONKS, A ;
SCUDIERO, DA ;
RUBINSTEIN, L ;
PLOWMAN, J ;
BOYD, MR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (14) :1088-1092
[28]   Kinetics and mechanism of the reaction between serum albumin and auranofin (and its isopropyl analogue) in vitro [J].
Roberts, JR ;
Xiao, J ;
Schleisman, B ;
Parsons, DJ ;
Shaw, CF .
INORGANIC CHEMISTRY, 1996, 35 (02) :424-433
[29]   Benzimidazol-2-ylidene Gold(I) Complexes Are Thioredoxin Reductase Inhibitors with Multiple Antitumor Properties [J].
Rubbiani, Riccardo ;
Kitanovic, Igor ;
Alborzinia, Hamed ;
Can, Suzan ;
Kitanovic, Ana ;
Onambele, Liliane A. ;
Stefanopoulou, Maria ;
Geldmacher, Yvonne ;
Sheldrick, William S. ;
Wolber, Gerhard ;
Prokop, Aram ;
Woelfl, Stefan ;
Ottt, Ingo .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (24) :8608-8618
[30]   A mass spectrometric investigation of the binding of gold antiarthritic agents and the metabolite [Au(CN)2]- stop to human serum albumin [J].
Talib, Jihan ;
Beck, Jennifer L. ;
Ralph, Stephen F. .
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2006, 11 (05) :559-570